Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Gene Replacement Therapy
1.2.3 Gene Silencing Therapy
1.2.4 Gene Editing Therapy
1.2.5 Enzyme Replacement Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy for Neurodegenerative Diseases Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals and Clinics
1.3.3 Research Institutions
1.3.4 Biotechnology Companies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Neurodegenerative Diseases Market Perspective (2018-2033)
2.2 Gene Therapy for Neurodegenerative Diseases Growth Trends by Region
2.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Gene Therapy for Neurodegenerative Diseases Historic Market Size by Region (2018-2023)
2.2.3 Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2024-2033)
2.3 Gene Therapy for Neurodegenerative Diseases Market Dynamics
2.3.1 Gene Therapy for Neurodegenerative Diseases Industry Trends
2.3.2 Gene Therapy for Neurodegenerative Diseases Market Drivers
2.3.3 Gene Therapy for Neurodegenerative Diseases Market Challenges
2.3.4 Gene Therapy for Neurodegenerative Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue
3.1.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue (2018-2023)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy for Neurodegenerative Diseases Revenue
3.4 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio
3.4.1 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Neurodegenerative Diseases Revenue in 2022
3.5 Gene Therapy for Neurodegenerative Diseases Key Players Head office and Area Served
3.6 Key Players Gene Therapy for Neurodegenerative Diseases Product Solution and Service
3.7 Date of Enter into Gene Therapy for Neurodegenerative Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Type
4.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Type (2018-2023)
4.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2024-2033)
5 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Application
5.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Application (2018-2023)
5.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
6.2 North America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
6.4 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
7.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
8.2 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023)
8.4 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
9.2 Latin America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
9.4 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
10.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
10.4 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Detail
11.1.2 Voyager Therapeutics Business Overview
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.1.4 Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.1.5 Voyager Therapeutics Recent Development
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Detail
11.2.2 Uniqure N.V. Business Overview
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Introduction
11.2.4 Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.2.5 Uniqure N.V. Recent Development
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Detail
11.3.2 Axovant Gene Therapies Business Overview
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Introduction
11.3.4 Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.3.5 Axovant Gene Therapies Recent Development
11.4 Novartis Ag
11.4.1 Novartis Ag Company Detail
11.4.2 Novartis Ag Business Overview
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Introduction
11.4.4 Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.4.5 Novartis Ag Recent Development
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Detail
11.5.2 Amicus Therapeutics Business Overview
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.5.4 Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.5.5 Amicus Therapeutics Recent Development
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Detail
11.6.2 Regenxbio Inc. Business Overview
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Introduction
11.6.4 Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.6.5 Regenxbio Inc. Recent Development
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Detail
11.7.2 Sarepta Therapeutics Business Overview
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.7.4 Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.7.5 Sarepta Therapeutics Recent Development
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Detail
11.8.2 Gensight Biologics Business Overview
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Introduction
11.8.4 Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.8.5 Gensight Biologics Recent Development
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Detail
11.9.2 Krystal Biotech Business Overview
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Introduction
11.9.4 Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.9.5 Krystal Biotech Recent Development
11.10 Avexis
11.10.1 Avexis Company Detail
11.10.2 Avexis Business Overview
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Introduction
11.10.4 Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.10.5 Avexis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Gene Replacement Therapy
Table 3. Key Players of Gene Silencing Therapy
Table 4. Key Players of Gene Editing Therapy
Table 5. Key Players of Enzyme Replacement Therapy
Table 6. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2018-2023)
Table 10. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2024-2033)
Table 12. Gene Therapy for Neurodegenerative Diseases Market Trends
Table 13. Gene Therapy for Neurodegenerative Diseases Market Drivers
Table 14. Gene Therapy for Neurodegenerative Diseases Market Challenges
Table 15. Gene Therapy for Neurodegenerative Diseases Market Restraints
Table 16. Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Gene Therapy for Neurodegenerative Diseases Market Share by Players (2018-2023)
Table 18. Global Top Gene Therapy for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2022)
Table 19. Ranking of Global Top Gene Therapy for Neurodegenerative Diseases Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Gene Therapy for Neurodegenerative Diseases Product Solution and Service
Table 23. Date of Enter into Gene Therapy for Neurodegenerative Diseases Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2023)
Table 27. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2024-2033)
Table 29. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2018-2023)
Table 31. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2024-2033)
Table 33. North America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 48. Voyager Therapeutics Company Detail
Table 49. Voyager Therapeutics Business Overview
Table 50. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 51. Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 52. Voyager Therapeutics Recent Development
Table 53. Uniqure N.V. Company Detail
Table 54. Uniqure N.V. Business Overview
Table 55. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product
Table 56. Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 57. Uniqure N.V. Recent Development
Table 58. Axovant Gene Therapies Company Detail
Table 59. Axovant Gene Therapies Business Overview
Table 60. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product
Table 61. Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 62. Axovant Gene Therapies Recent Development
Table 63. Novartis Ag Company Detail
Table 64. Novartis Ag Business Overview
Table 65. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product
Table 66. Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 67. Novartis Ag Recent Development
Table 68. Amicus Therapeutics Company Detail
Table 69. Amicus Therapeutics Business Overview
Table 70. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 71. Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 72. Amicus Therapeutics Recent Development
Table 73. Regenxbio Inc. Company Detail
Table 74. Regenxbio Inc. Business Overview
Table 75. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product
Table 76. Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 77. Regenxbio Inc. Recent Development
Table 78. Sarepta Therapeutics Company Detail
Table 79. Sarepta Therapeutics Business Overview
Table 80. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 81. Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 82. Sarepta Therapeutics Recent Development
Table 83. Gensight Biologics Company Detail
Table 84. Gensight Biologics Business Overview
Table 85. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product
Table 86. Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 87. Gensight Biologics Recent Development
Table 88. Krystal Biotech Company Detail
Table 89. Krystal Biotech Business Overview
Table 90. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product
Table 91. Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 92. Krystal Biotech Recent Development
Table 93. Avexis Company Detail
Table 94. Avexis Business Overview
Table 95. Avexis Gene Therapy for Neurodegenerative Diseases Product
Table 96. Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 97. Avexis Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy for Neurodegenerative Diseases Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Market Share by Type: 2022 VS 2033
Figure 3. Gene Replacement Therapy Features
Figure 4. Gene Silencing Therapy Features
Figure 5. Gene Editing Therapy Features
Figure 6. Enzyme Replacement Therapy Features
Figure 7. Global Gene Therapy for Neurodegenerative Diseases Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Gene Therapy for Neurodegenerative Diseases Market Share by Application: 2022 VS 2033
Figure 9. Hospitals and Clinics Case Studies
Figure 10. Research Institutions Case Studies
Figure 11. Biotechnology Companies Case Studies
Figure 12. Others Case Studies
Figure 13. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 14. Global Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region: 2022 VS 2033
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market Share by Players in 2022
Figure 18. Global Top Gene Therapy for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue in 2022
Figure 20. North America Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 22. United States Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 26. Germany Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Share by Region (2018-2033)
Figure 34. China Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 42. Mexico Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 46. Turkey Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Voyager Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 49. Uniqure N.V. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 50. Axovant Gene Therapies Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 51. Novartis Ag Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 52. Amicus Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 53. Regenxbio Inc. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 54. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 55. Gensight Biologics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 56. Krystal Biotech Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 57. Avexis Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed